MARK OWEN HENRY
Pilots at Evergreen Dr, North Andover, MA
License number
Massachusetts A0827450
Issued Date
Aug 2016
Expiration Date
Aug 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
35 Evergreen Dr, North Andover, MA 01845
Professional information
Methods Of Modulating Protein Homeostasis, Metabolic Syndrome, Heavy Metal Intoxication And Nrf2 Transcription Factors
US Patent:
2010008, Apr 8, 2010
Filed:
Sep 23, 2009
Appl. No.:
12/565579
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
Assignee:
BACH PHARMA INC. - North Andover MA
International Classification:
A61K 38/43, A61K 31/502, A61K 31/4985, A61K 31/65, A61P 3/00, A61P 29/00
US Classification:
424 941, 514248, 514249, 514154
Abstract:
Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.
Modulation Of Cell Fates And Activities By Phthalazinediones
US Patent:
2009003, Feb 5, 2009
Filed:
Mar 7, 2008
Appl. No.:
12/044716
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
Assignee:
Bach Pharma, Inc. - North Andover MA
International Classification:
A61K 31/502, A61P 3/00, A61K 31/573, A61K 31/5025, A61P 29/00, A61P 25/00, A61P 37/00, A61P 35/00
US Classification:
514154, 514248, 514171, 514249
Abstract:
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.
Modulation Of Cell Fates And Activities By Phthalazinediones
US Patent:
2014003, Jan 30, 2014
Filed:
Feb 11, 2013
Appl. No.:
13/764365
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
International Classification:
A61K 31/502, A61K 38/44, A61N 5/10, A61K 31/65, A61K 31/519, A61K 31/573, A61K 31/197
US Classification:
424450, 424489, 514248, 514171, 424 944, 514154, 514249, 600 1
Abstract:
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.
Modulation Of Cell Fates And Activities By Diketo Phthalazines
US Patent:
6953799, Oct 11, 2005
Filed:
Oct 30, 2002
Appl. No.:
10/283647
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
Assignee:
Bach Pharma, Inc. - North Andover MA
International Classification:
A61K031/495
US Classification:
514248
Abstract:
Phthalazine diones that function as intracellular redox modulators and buffers are used to treat stressed cells in various disease states in which the intracellular redox status is impaired. By optimal buffering of aberrant redox states, phthalazine diones enhance the cellular processes essential for survival and augment the conventional or other external therapies necessary for treatment. The phthalazine diones of the invention thus regulate cell growth, differentiation, or death to serve as essential adjunctive therapy for the stressed host in various disease states.
Modulation Of Cell Fates And Activities By Phthalazinediones
US Patent:
2007014, Jun 21, 2007
Filed:
Jan 30, 2007
Appl. No.:
11/699853
Inventors:
Mark Henry - North Andover MA, US
William Lynn - Hillsborough NC, US
William Lynn - Hillsborough NC, US
Assignee:
Bach Pharma, Inc. - North Andover MA
International Classification:
A61K 38/05, A61K 31/573, A61K 31/502, A61K 31/65, A61K 31/55, A61K 31/4743, A61K 31/385
US Classification:
514018000, 514171000, 514248000, 514440000, 514410000, 514250000, 514554000, 514154000, 514217050, 514562000, 424450000, 424451000
Abstract:
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.
Modulation Of Cell Fates And Activities By Phthalazinediones
US Patent:
7691819, Apr 6, 2010
Filed:
Feb 4, 2008
Appl. No.:
12/025193
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
Assignee:
Bach Pharma, Inc. - North Andover MA
International Classification:
A61K 38/00, A61K 31/56, A61K 31/525, A61K 31/385, A61K 31/195, A61K 31/19
US Classification:
514 18, 514171, 514248, 514440, 514562, 514570
Abstract:
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.
Methods Of Treating Intestinal Diseases And Inflammatory Conditions Related To Hiv-Aids
US Patent:
2010025, Oct 7, 2010
Filed:
Feb 19, 2010
Appl. No.:
12/709108
Inventors:
Mark O. HENRY - North Andover MA, US
Williams S. LYNN - Hillsborough NC, US
Williams S. LYNN - Hillsborough NC, US
Assignee:
BACH PHARMA, INC. - North Andover MA
International Classification:
A61K 31/502, A61K 9/127, C07D 237/30, A61P 1/00
US Classification:
424450, 514248, 544237
Abstract:
Provided herein are methods of treating intestinal diseases or inflammatory conditions, including HIV-AIDS, in which oxidative stress is a triggering or exacerbating factor by administering GVT to a patient suffering from the condition such that the condition is treated.
Pharmaceutical Grade Phthalazinediones, Process For Their Preparation And Pharmaceutical Compositions Containing Them
US Patent:
2010022, Sep 2, 2010
Filed:
Feb 5, 2010
Appl. No.:
12/701088
Inventors:
Mark O. HENRY - North Andover MA, US
William S. LYNN - Hillsborough NC, US
William S. LYNN - Hillsborough NC, US
Assignee:
BACH PHARMA, INC. - North Andover MA
International Classification:
C07D 237/32, G01N 33/00
US Classification:
544237, 436106
Abstract:
The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione for administration to a human or animal. The manufacturing methods identify and isolate starting materials, and prepare intermediate products, which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final phthalazinedione products.
Modulation Of Cell Fates And Activities By Phthalazinediones
US Patent:
7326690, Feb 5, 2008
Filed:
Aug 8, 2005
Appl. No.:
11/199394
Inventors:
Mark O. Henry - North Andover MA, US
William S. Lynn - Hillsborough NC, US
William S. Lynn - Hillsborough NC, US
Assignee:
Bach Pharma, Inc. - North Andover MA
International Classification:
A61K 38/00, A61K 31/56, A61K 31/495, A61K 31/385, A61K 31/195
US Classification:
514 18, 514171, 514248, 514440, 514562, 514570
Abstract:
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.